Navigation Links
FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation
Date:12/11/2007

NASDAQ: CRME TSX: COM

VANCOUVER and DEERFIELD, IL, Dec. 11 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has recommended that the FDA approve KYNAPID(TM), the intravenous formulation of vernakalant hydrochloride, an investigational new drug for rapid conversion of acute atrial fibrillation (AF).

At the panel review conducted today in Maryland, the members voted 6 to 2 in favour of recommending to the FDA that KYNAPID be approved for the rapid conversion of acute AF to sinus rhythm. If approved, KYNAPID will be the first new pharmacologic therapy for the conversion of AF in eight years.

"We are pleased with the committee's recommendation," said William E. Fitzsimmons, PharmD, Senior Vice President, Research & Development at Astellas. "We strongly believe in the therapeutic value of KYNAPID based on clinical trial data and are confident it will be an important therapy for people with atrial fibrillation."

"We welcome the committee's recommendation for approval, and look forward to the FDA completing their review and acting on the application early in the new year," stated Bob Rieder, Chief Executive Officer and Chairman of Cardiome. "People with atrial fibrillation suffer significant disease burden, and we are pleased to move an important step closer to providing doctors with an important tool for meeting this critical unmet medical need."

The Cardiovascular and Renal Drugs Advisory Committee is convened on request of the FDA, and reviews and evaluates available data concerning the safety and effectiveness of human drug products for use in the treatment of cardiovascular and renal disorders. Although the Committee provides recommendations to the Agency and suggests a course of action, final
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
2. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
3. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
4. Patient Safety Authority Board of Directors Names Infection Advisory Panel
5. Broker a Suite of Research & Advisory Services to Enhance Human Resources
6. Lynn Clark Callister, National Leader in Maternal-Child Health Nursing, Joins March of Dimes Advisory Council
7. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
8. Delta Dental Plans Association Forms National Scientific Advisory Committee
9. Alter+Care Creates the Advisory Board
10. Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors
11. Susan G. Komen for the Cure Appoints Dr. Amelie G. Ramirez to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... Rockford, IL (PRWEB) May 19, 2013 Beginning ... Rock River Valley Blood Center (RRVBC) will feature “Hot Dog ... and Belvidere. RRVBC will provide hot dogs and all ... feature ice-cold slushies each day throughout the summer. “Donors are ... to maintain a stable and adequate blood supply. This ...
(Date:5/19/2013)... 2013 HealthEconomics.Com , the global ... to unveil a new and exciting service: HE-Xpo: a ... powerful array of real-time communication tools to expand their ... abroad. , HE-Xpo is powered by OnStream Media’s ... and feel of being at a physical trade show, ...
(Date:5/19/2013)... 2013 The Da Vinci robot lawyers ... in the nation’s first trial involving a Da Vinci ... State Superior Court, was filed by the widow of ... complications in a robot-assisted prostate removal, according to a ... robotic surgery lawsuit alleges those complication’s hastened his ...
(Date:5/18/2013)... 18, 2013 Daily Gossip issued a press ... review on their page. John Colston, Daily Gossip’s spokesperson, told ... Hadsall’s revolutionizing 14-Day Rapid Fat Loss Plan . ... carbs are healthy at a time when nutritionists and fat ... caloric products. , The diet is based on the ...
(Date:5/18/2013)... American Gastroenterological Association (AGA) Research Foundation is pleased ... honorees are outstanding young gastroenterologists working toward independent ... with this award, their research time will be ... future of our field. AGA is committed to ... for promising research developments and new therapies," said ...
Breaking Medicine News(10 mins):Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 2Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 3Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 4Health News:AGA Research Foundation Research Scholar Awards advance the work of promising gastroenterologists 2
... , ... ... ... ...
... ... role , ... February 25, 2010 -- LocumTenens.com has named Lisa Kaeck as Executive Vice ... of service at LocumTenens.com., , , , ,A founding partner of LocumTenens.com, Kaeck has more ...
... ... ... ... ...
... , ... ... , , ... ...
... ... ... ... Outlawing Health Insurance Monopolies Would Be Good for Doctors, Patients , ...
... cancer patients receiving induction chemotherapy followed by radiation to ... disability and almost half experienced no eating or swallowing ... presented at the Multidisciplinary Head and Neck Cancer Symposium, ... removal with permanent tracheotomy is the current standard treatment ...
Cached Medicine News:Health News:Good Parenting Triumphs Over Prenatal Stress 2Health News:Good Parenting Triumphs Over Prenatal Stress 3Health News:Good Parenting Triumphs Over Prenatal Stress 4Health News:Good Parenting Triumphs Over Prenatal Stress 5Health News:Good Parenting Triumphs Over Prenatal Stress 6Health News:LocumTenens.com Names Lisa Kaeck Executive Vice President 2Health News:Highmark Inc. Prepares Now for the Diversity Boom Ahead 2Health News:Highmark Inc. Prepares Now for the Diversity Boom Ahead 3Health News:Highmark Inc. Prepares Now for the Diversity Boom Ahead 4Health News:Pelosi Remarks at Bipartisan Meeting at Blair House on Health Insurance Reform 2Health News:Pelosi Remarks at Bipartisan Meeting at Blair House on Health Insurance Reform 3Health News:Pelosi Remarks at Bipartisan Meeting at Blair House on Health Insurance Reform 4Health News:Pelosi Remarks at Bipartisan Meeting at Blair House on Health Insurance Reform 5Health News:Pelosi Remarks at Bipartisan Meeting at Blair House on Health Insurance Reform 6Health News:Pelosi Remarks at Bipartisan Meeting at Blair House on Health Insurance Reform 7Health News:Doctors Applaud House Vote to Remove Anti-Trust Exemption for Health Insurers 2Health News:Doctors Applaud House Vote to Remove Anti-Trust Exemption for Health Insurers 3
(Date:5/17/2013)... Conn. , May 17, 2013 /PRNewswire-iReach/ -- ... and recombinant proteins, is placing renewed emphasis on ... the rise as a number of factors are ... for pharmaceutical makers and their delivery device partners ... previously refractory conditions, the growing trend toward self-administration ...
(Date:5/17/2013)... 17, 2013  Boehringer Ingelheim will contribute to ... the American Thoracic Society International Conference (ATS 2013) ... 17 – 22. Data will highlight ... treatment of chronic obstructive pulmonary disease (COPD) [Spiriva® ... investigational compounds for asthma, idiopathic pulmonary fibrosis (IPF) ...
(Date:5/17/2013)... (EURONEXT: SAN and NYSE: SNY ) announced today ... examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), ... primary endpoint assessed the proportion of patients achieving >/=35% ... previous trials, the most common adverse events were anemia, ... at an upcoming medical congress. MF ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
... BOZEN, SUD-TIROL, Italy , July 27, 2010 ... assets from, Italy -based MEDarchiver S.r.l. and Biomedical Technology Consulting S.r.l.,merging ... market, and conducting a re-organization of its,Executive Management, expecting to close ... , , ...
... Sysmex America, Inc., a leading medical diagnostic ... to debut its expanded cell image analysis portfolio during ... Conference and Clinical Lab Expo July 25 - ... DM1200 and DM96 systems for the mid-size to larger ...
Cached Medicine Technology:Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies 2Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies 3Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies 4Sysmex America to Launch Complete Cell Image Analysis Portfolio at AACC 2Sysmex America to Launch Complete Cell Image Analysis Portfolio at AACC 3
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... Featured Products are kept ... and are offered as ... regular or extra long ... with insulation, flush ports, ...
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: